Published in Am Rev Respir Dis on September 01, 1984
Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest (1990) 5.21
Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med (1991) 2.46
Enhanced interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest (1995) 1.85
Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol (1986) 1.37
Effect of chemotactins released by Staphylococcus aureus and Pseudomonas aeruginosa on the murine respiratory tract. Infect Immun (1985) 1.14
Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med (2006) 1.10
Immune aspects of sarcoidosis. Postgrad Med J (1988) 1.04
Phenotypic and functional changes in alveolar macrophages contribute to the pathogenesis of pulmonary sarcoidosis. Clin Exp Immunol (1988) 1.03
Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. Am J Pathol (1998) 0.89
Effects of inflammation and fibrosis on pulmonary function in diffuse lung fibrosis. Thorax (1990) 0.89
Gammadelta T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis. Transl Res (2009) 0.89
Alveolar macrophages from patients with bronchogenic carcinoma and sarcoidosis similarly express monocyte antigens. Clin Exp Immunol (1991) 0.88
Bronchiolitis obliterans and pneumonia induced in young dogs by experimental adenovirus infection. Am J Pathol (1985) 0.88
The K veim response: still useful, still a puzzle. Thorax (1987) 0.88
Establishment and characterization of an antigen-specific T-cell line from liver granulomas of Schistosoma mansoni-infected mice. Infect Immun (1987) 0.87
Local macrophage proliferation in multinucleated giant cell and granuloma formation in experimental Goodpasture's syndrome. Am J Pathol (1995) 0.87
Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis. Immunology (1989) 0.83
Collagenase, elastase, and nonspecific protease production by vigorous or immunomodulated liver granulomas and granuloma macrophages/eosinophils of S mansoni-infected mice. Am J Pathol (1985) 0.83
Immunological features of lung lavage cells from patients with primary biliary cirrhosis may reflect those seen in pulmonary sarcoidosis. Gut (1990) 0.79
Persistent biological reactivity of quartz in the lung: raised protease burden compared with a non-pathogenic mineral dust and microbial particles. Br J Ind Med (1991) 0.79
Stachybotrys chartarum-induced hypersensitivity pneumonitis is TLR9 dependent. Am J Pathol (2011) 0.78
Diagnostic value of strain echocardiography, galectin-3, and tenascin-C levels for the identification of patients with pulmonary and cardiac sarcoidosis. Lung (2014) 0.76
Procaterol inhibits lung fibroblast migration. Inflammation (2009) 0.76
Inhaled corticosteroids in pulmonary sarcoidosis. Postgrad Med J (1991) 0.75
Fluctuation in ventricular sensing leading to underdetection of ventricular fibrillation in a patient with cardiac sarcoidosis. J Interv Card Electrophysiol (2009) 0.75
Laminin--a glycoprotein from basement membranes. J Biol Chem (1979) 12.49
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med (1999) 10.62
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol (1985) (1986) 6.86
Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol (1979) 5.94
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Idiopathic pulmonary fibrosis. N Engl J Med (2001) 5.49
Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature (1992) 5.45
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med (1976) 4.85
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
A neutrophil chemotactic factor from human C'5. J Immunol (1969) 4.46
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Analysis of cellular and protein content of broncho-alveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest (1977) 4.21
Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med (1981) 4.02
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). N Engl J Med (1984) 3.73
Distribution and immunoelectron microscopic localization of laminin, a noncollagenous basement membrane glycoprotein. Lab Invest (1980) 3.64
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc Natl Acad Sci U S A (1980) 3.57
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol (1985) (1987) 3.51
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Chicken soup inhibits neutrophil chemotaxis in vitro. Chest (2000) 3.48
Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest (1985) 3.40
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem (1980) 3.28
Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med (2001) 3.25
Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet (1993) 3.22
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med (1981) 3.08
Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA (1994) 3.03
Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood (2001) 3.01
Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet (1989) 3.01
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature (1986) 2.94
Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med (1987) 2.81
Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol (2000) 2.81
Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med (1983) 2.71
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 2.62
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med (1987) 2.62
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest (1992) 2.62
Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med (1970) 2.61
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 2.57
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem (2001) 2.50
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis (1997) 2.48
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest (1988) 2.46
Evaluation of clinical parameters to predict Mycobacterium tuberculosis in inpatients. Arch Intern Med (2000) 2.46
Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst (1998) 2.44
Molecular basis of alpha-1-antitrypsin deficiency. Am J Med (1988) 2.40
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med (1978) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes. Lancet (1980) 2.35
Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci U S A (1981) 2.34
Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest (1982) 2.33
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest (1992) 2.33
Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther (2011) 2.33
Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis (1979) 2.31
Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med (1984) 2.30
Human type III collagen gene expression is coordinately modulated with the type I collagen genes during fibroblast growth. Biochemistry (1986) 2.28
Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders. J Clin Invest (1983) 2.27